Stay up to date on recent advances in oncology nursing and patient care.
Imlunestrant vs Elacestrant: MOA and Clinical Trial Differences
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Fixed-Duration Mosunetuzumab/Polatuzumab Active in R/R MCL
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL
Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression
The Reality of VTE: How to Best Address in Cancer Care
AI Decision Support Tools Serve as Copilots in Cancer Care
Toxicity Monitoring, Management Crucial for Tarlatamab in ES-SCLC
Cancer Drug Repository Network Yields $18M in Patient Savings
